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What do recent epidemiological studies tell us about the risk of cancer from radiation 
doses typical of diagnostic radiography? 
 
Abstract: 
The last five years have seen unprecedented efforts to gain further understanding of the 
cancer risks following exposure to radiation doses below 100 mGy. Research has focused on 
occupationally exposed groups, populations exposed to elevated background radiation levels 
and children undergoing computed tomography scans. This review summarises the main 
findings of these studies and discusses the implications for diagnostic radiography. On 
balance, recent studies strengthen the association between radiation exposure at diagnostic 
dose levels and the risk of developing cancer at low doses. Although subject to considerable 
uncertainties, the risks to patients and staff from exposure to x-rays at diagnostic dose levels 
appear to be small, but non-zero. Despite the improved statistical power of recent studies, a 
number of shortcomings are apparent. These include dosimetric uncertainties and the 
potential confounding effects of cancer predisposing conditions and pre-existing tumours. 
 
Introduction: 
Radiation protection is primarily based on the known association between ionising radiation exposure 
and the increased lifetime risk of developing cancer. Until recently, epidemiological studies have 
lacked sufficient statistical power to demonstrate excess cancer risks at doses below around 100 
milligray (mGy). Risk estimates are based on downward extrapolation of the risks at higher doses, 
assuming a linear relationship between dose and risk, without a threshold, below which there is no 
risk [1-3]. This so-called linear-no-threshold (LNT) approach remains controversial [4, 5], however, 
with authors claiming the model either underestimates [6], or overestimates [7, 8] the risks at low 
doses. The implications of this uncertainty for public health, the nuclear industry and healthcare are 
profound. Consequently, the last five years have seen major efforts to gain further understanding of 
the risks at doses below 100 mGy, including updated studies of occupational exposures and 
populations residing in high background radiation areas, as well as new cohorts of children 
undergoing computed tomography (CT) scans. The aim of this review was to provide a concise 
summary of these studies and to discuss the implications of findings for radiation protection. Risks are 
presented in several forms, i.e. relative risk (RR), excess relative risk (ERR), incidence rate ratio 
(IRR), hazard ratio (HR) and standardised incidence ratio (SIR), along with respective 95% 
confidence intervals (CI). A short description of these measures is provided in the supplementary 
materials for this review.  
 
Computed tomography studies: 
CT scans deliver effective doses of approximately 1-15 mSv [9-12], depending on body part and 
patient age. Mean absorbed doses to organs within the exposed region are generally below 30 mGy 
for head scans and 20 mGy elsewhere [10-13]. These doses are thus towards the upper end of the 
range of doses encountered in diagnostic imaging. Since 2012, seven epidemiological studies 
investigating the cancer risks from CT scans have been published [14-20], based on five national 
cohorts. All have focused on children or young adults (under 22 years). The potential for adult studies 
has been assessed [21], though to date, none have been published.  
Pearce et al [14] conducted a retrospective observational study of nearly 180,000 British children and 
adolescents receiving CT scans between 1985 and 2002. Neoplasms developing within 5 years (brain 
tumours) or 2 years (leukaemia) following exposure were excluded from the analysis. After around 15 
years of follow-up, a significant association between radiation dose and incidence of leukaemia 
(ERR=0.036 mGy-1 95% CI: 0.005, 0.120) and brain tumours (ERR=0.023 mGy-1, 95% CI: 0.010, 
0.049) was detected, in relation to red bone marrow and brain doses, respectively. For both diseases, 
the dose/risk relationship was best described by a linear model. The authors quote equivalent ERR 
figures from the ‘Life Span Study’ (LSS) of atomic bombing survivors in Hiroshima and Nagasaki of 
0.045 mSv-1 for leukaemia (95% CI: 0.016, 0.188) and 0.0061 mSv-1 for brain tumours (95% CI: 
0.0001, 0.639) in the 0-19 years age group, based on the same length of follow-up.  However, the 
ERR quoted by Pearce et al for leukaemia includes myelodysplastic syndrome (MDS), which is not 
usually regarded as a form of leukaemia [22] and not included in the LSS  risk estimate. After 
excluding MDS from the results of Pearce et al, the ERR is reduced to 0.019 mSv-1 and no longer 
statistically significant. The risk of brain tumours was found to increase with increasing age at 
exposure, ranging from 0.005 Gy-1 at 0-5 years to 0.041 mGy-1 after 15 years. This finding, while not 
unprecedented, contrasts with the LSS [23] and studies of children irradiated for scalp ringworm 
(tinea capitis) [24] and skin haemangioma [25] in which the reverse pattern was found. There was a 
suggestion that females were at a greater risk than males of brain tumours following CT scans (ERR 
of 0.028 mSv-1, versus 0.016, p=0.085). Again, the reverse pattern was observed among the LSS 
cohort (p=0.02) [23].  
A second study by Matthews et al [15] involved a data linkage analysis of 680,211 Australian patients 
receiving CT scans before age 19 years, between 1985 and 2005, compared to 10,259,569 unexposed 
individuals. With a mean follow-up duration of 9.3 years and an exclusion period of  just one year, 
cancer incidence in the exposed group was 24% greater than in the unexposed group (incidence rate 
ratio (IRR)= 1.24, 95% CI: 1.20, 1.29 for all cancers). This increase, the authors state, is ‘mostly due 
to irradiation’. Increases for almost all cancer sites were found, including those with limited previous 
association with radiation, such as Hodgkin's lymphoma and melanoma [26, 27], but no increase was 
found for breast cancer (IRR= 0.99) and lymphoid leukaemia (0.96), both of which are strongly 
associated with radiation [28, 29] (the former finding is perhaps unsurprising given the short follow-
up).  Interestingly, the IRR for brain tumours was significantly raised following scans of regions other 
than the brain (1.51, 95% CI: 1.19, 1.91). 
Brain tumours have been previously associated with ionising radiation exposure, most notably 
following cranial radiotherapy for acute lymphoblastic leukaemia [30] or previous brain tumours [31]. 
The association appears to be somewhat stronger for benign tumours such as meningiomas and 
schwannomas, than for malignant gliomas [32, 33]. The latency period (i.e. the time between 
exposure and diagnosis) for meningioma development following radiotherapy is typically around 20 
years, ranging from 10 to 30 [30, 34, 35], while for gliomas, the latency is around 10 years [31, 34-
36]. Many such tumours are detected at an asymptomatic stage via screening programs in these 
patient groups [30]. For other exposed populations, including children given radiotherapy for scalp 
ringworm (mean dose= 1.4 Gy) [37], skin haemangioma [25], or atomic bombing survivors [38], the 
latency period is longer still, at around 35-40 years. Yet the study by Mathews et al [15] reported a 
significantly raised IRR for brain tumours in the period 1-4 years following head CT scans (3.24, 95% 
CI: 2.61, 4.02), with declining IRR figures for the periods 5-9 (IRR=2.42), 10-14 (1.80) and >15 years 
(1.74). The appearance of brain tumours so soon after exposure is highly unusual and raises concerns 
that these diseases were present at the time of, or indeed were the indication for, the CT scan in the 
first place [39, 40]. Alternatively, the condition for which the patient underwent a CT scan may itself 
be a risk factor for developing cancer [29]. Examples include neurofibromatosis (NF) and tuberous 
sclerosis complex (TSC) [41, 42]. This so-called ‘confounding by indication’ has become one of the 
leading concerns among radiation epidemiologists and the dominant focus of more recent studies. 
A re-examination of the British CT cohort, first reported by Pearce et al [14], was conducted by 
Berrington de González et al [19], who analysed pathology and radiologist reports and comments 
written in the radiology information system (RIS) to identify predisposing conditions and pre-existing 
tumours. Previous cancers and possible previous cancers, were found to have the largest impact, 
resulting in a reduction in ERR for brain tumours by around 57% (0.023 mGy-1 to 0.010) and for 
leukaemia by 44% (0.036 mGy-1 to 0.020). There was little evidence that patients with leukaemia pre-
disposing conditions received higher bone marrow doses, meaning ERR figures were almost 
unchanged when these patients were excluded. Patients with CNS tumour predisposing conditions 
received slightly higher brain doses. Excluding these patients reduced the ERR by about 17% (0.023 
mGy-1 to 0.019). 
Huang and colleagues [16] studied cancer incidence ascertained from insurance records among 28,185 
Taiwanese subjects undergoing CT head scans while aged under 18 years between 1998 and 2006, 
compared to 97,668 unexposed individuals. Patients with NF, hamartomas, multiple endocrine 
neoplasia and disorders of the adrenal gland were excluded, leaving a sample of 24,418 children. For 
all cancer types combined, based on an exclusion period of 2 years, no significant increase was seen 
among the exposed cohort (hazard ratio = 1.29, 95% CI: 0.90, 1.85). A significant increase in brain 
tumours was found (HR=2.56, 95% CI: 1.44, 4.54), based on 19 cases, of which 14 were benign. The 
study has a number of limitations, including the lack of any dose estimation at all, and the failure to 
include non-head CT exposures in the analysis. Patients with a number of well-known cancer-
predisposing conditions, such as TSC, ataxia telangiectasia (AT) or Li Fraumeni syndrome do not 
appear to have been excluded, thus may have confounded the results. 
Journy et al [17] investigated cancer incidence among 67,274 French children receiving CT scans 
before the age of 10 years between 2000 and 2010. Patients with predisposing conditions, including 
NF, AT, organ transplantation, HIV/AIDS and other phacomatoses (including TSC) were identified 
from discharge notes. Dose estimates were based on examination protocols. Following a very short 
follow-up time (median= 4 years), the authors report a decrease in ERR after adjusting for 
predisposing conditions, falling from 0.022 mGy-1 to 0.012 for CNS tumours, from 0.057 mGy-1 to 
0.047 for leukaemia, and from 0.018 mGy-1 to 0.008 for lymphoma. However, the ERR for children 
without such conditions appears to be higher than the unadjusted ERR for the whole cohort, while the 
ERR for children with predisposing conditions is close to zero. Responses by Cardis and Bosch de 
Basea [43] and Muirhead [44] argue that this implies the ERR was modified by predisposing factors 
rather than confounded. In a further analysis [20] of the same cohort using Cox proportional hazard 
models, a pattern of increasing risk of CNS tumours and leukaemia with increasing dose was seen 
(HR per 10 mGy: 1.07 and 1.17 respectively) in children without predisposing conditions, while for 
those with these conditions, the reverse pattern was seen (HR per 10 mGy: 0.80 and 0.57, 
respectively).  
Krille et al [18] investigated cancer incidence among 44,584 German children undergoing 71,073 CT 
scans between 1980 and 2010. Again, efforts were made to identify subjects with cancer predisposing 
conditions or those examined for suspected cancer. After excluding these patients, a significantly 
raised standardised incidence ratio (SIR) was found for all cancer sites combined (SIR=1.54, 95% CI: 
1.05, 2.19), along with a non-significantly raised SIR for leukaemia (1.79, 95 % CI: 0.92, 3.12) and 
CNS tumours (1.20, 95% CI: 0.44, 2.61). A dose response was obtained by calculating the hazard 
ratio for the whole cohort (including subjects with predisposing conditions). A significantly increased 
HR was found for brain tumours (1.008 mGy-1, 95% CI: 1.004, 1.013), but not for leukaemia (1.009, 
95% CI: 0.981, 1.037) or for all tumours combined (0.986, 95% CI: 0.944, 1.030). 
Dose estimates in the above studies [14-20], where provided, were non-individualised, based on age 
adjusted ‘typical’ doses for the equipment or year of scan. Future studies may utilise examination-
specific metadata recorded in the image DICOM header [45, 46]. Potential reasons for 
underestimation of doses includes missing procedures (e.g. pre- and post-contrast head scan listed as 
simply ‘CT head’) or unrecorded repeat slices. Contrast agent administration could also result in 
higher absorbed doses than expected [47], although the overall impact of contrast agents on doses and 
associated risks is currently unknown. Potential for overestimation of doses includes RIS entries for 
scans that weren’t conducted or ‘scans’ that were in fact multiplane reconstructions, scout images or 
non-radiological procedures carried out in the CT room. None of the above studies included doses 
from other forms of medical imaging, including nuclear medicine or fluoroscopy.  
 
Occupational exposure studies: 
Occupationally exposed individuals make suitable subjects in radiation epidemiology studies due to 
widespread dose monitoring, potentially large sample sizes and the protracted nature of exposures. A 
study published in 2005, involving a pooled analysis of cancer mortality among 407,391 nuclear 
industry workers in 15 countries [48], exposed to an average cumulative dose of 19.4 mSv,  reported a 
significantly increased risk for all cancers except leukaemia (ERR=0.97 Sv-1, 95% CI: 0.14, 1.97) and 
a non-significantly raised risk for leukaemia (ERR=1.93, 95% CI: <0, 8.47). The study has drawn 
comment concerning the potential confounding effect of smoking and the unusually high ERR among 
Canadian workers [49, 50]. A reanalysis of the Canadian data was conducted by Zablotska et al [51], 
who reported a much greater solid cancer ERR among workers employed between 1956 and 1964 
(7.78 Sv-1, 95% CI: 1.88, 19.5) than for those employed after 1964 (-1.20, 95% CI: -1.47, 2.39). 
Excluding the Canadian data from the 15-country study, the ERR for solid cancers was reduced to 
0.58 Sv-1 (95% CI: -0.10, 1.39) [52], which is reasonably close to the linear ERR mortality estimate 
from the LSS of 0.32 Sv-1 [3]. A more recent analysis was conducted by Leuraud et al [53] on a subset 
of the 15-country study called INWORKS (International Nuclear Workers Study), focusing on 
308,297 radiation-monitored workers in the UK, USA and France, receiving a mean yearly bone 
marrow dose of 1.1 mGy (cumulative mean= 15.9 mGy, cumulative median= 2.1 mGy). Mortality 
was significantly raised for leukaemia (ERR=2.96 Gy-1, 95 CI: 1.17, 5.21), but not for non-Hodgkin’s 
lymphoma (ERR=0.47 Gy-1, 95% CI: -0.76, 2.03). The INWORKS cohort was subject to a further 
analysis by Richardson et al [54] examining cancer mortality for all sites except leukaemia, based on 
a mean cumulative colon dose of 20.9 mGy (median= 4.1 mGy). A significantly elevated risk was 
found (ERR=0.48 Gy-1, 95% CI: 0.2, 0.79). This risk is 50% lower than reported in the above-
mentioned study by Cardis et al [52], though still a little higher than that of the LSS. Despite the 
reduced sample size, compared to the 15-country study, the longer follow-up and larger number of 
deaths of the INWORKS cohort yield much greater statistical power. Limitations include the potential 
confounding effect of smoking, considerable dosimetric uncertainties and limited information on 
neutron dose or internal radionuclides [55]. 
Two recent studies have focused on the offspring of female workers at the Mayak nuclear facility in 
Russia, providing the opportunity to assess the lifetime cancer risks following in utero exposures. The 
median estimated in utero dose from gamma radiation for those with a dose greater than zero was 
18.7 mSv (max= 945 mSv) [56]. Doses due to plutonium were extremely low. No significant 
association was found by Schonfeld et al [57] for mortality for solid cancers (ERR= −0.1 Gy-1, 95% 
CI: <−0.1, 4.1) or leukaemia (ERR= −0.8 Gy-1, 95% CI: <−0.8, 46.9). The solid cancer ERR was 
raised, however, for attained ages below 15 years (ERR= 50 Gy-1). Though based on only 2 cases and 
with an exceptionally wide confidence interval (-0.1, 1334), this latter finding is similar to that of the 
Oxford Survey or Childhood Cancers (OSCC) (ERR of 51 Gy-1) [58]. A later study by Tsareva and 
colleagues [56] focused on solid cancer incidence, with the advantage of longer follow-up and a 
greater number of cases. Again, no association with radiation exposure was found (ERR= -1.0 Gy-1, 
95% CI: N/A, 0.5). These findings, while surprising, are subject to considerable statistical 
imprecision, thus are not incompatible with those of the OSCC and should not be interpreted as 
conclusive evidence that in utero exposure does not increase cancer risk. 
Previous studies of medical radiation workers, including the US Radiologic Technologists Study [59], 
have found evidence of increased rates of leukaemia and cancers of the skin and breast among those 
employed before 1950, but mixed evidence for those employed thereafter [60-62]. A recent update of 
a cohort study of 27,011 Chinese diagnostic x-ray workers [63] exposed to a mean cumulative colon 
dose, estimated from badge readings, of 86 mGy (median= 42 mGy) found a significantly increased 
incidence of solid cancer (ERR= 0.87 Gy-1, 95% CI: 0.48, 1.45) compared to 25,782 non-exposed 
physicians. The potential socioeconomic differences in these two groups, along with substantial 
dosimetric uncertainties are acknowledged limitations. The doses received by most x-ray staff have 
decreased markedly, with mean estimated cumulative breast dose falling from 560 mGy for US 
technologists first employed in the 1930s, to 2.8 mGy in the 1990s [64]. The associated risks, 
therefore, are likely to be small. 
 
Background radiation studies: 
Residents of a number of areas are exposed to elevated radiation levels as a result of natural 
radioactivity or industrial pollution. Previous studies of these populations have produced mixed 
results, hindered by dose uncertainties and small sample sizes [65]. A recent case-control study with 
reasonably high statistical power was conducted by Kendall and colleagues [66] who matched 27,447 
children living in Great Britain who developed cancer with 36,793 cancer-free controls. Radiation 
doses were estimated based on the mother’s residence at the time of the child’s birth and a national 
survey of natural background radiation levels [67]. For leukaemia, a significantly raised relative risk 
of 1.12 per mSv cumulative bone marrow dose from gamma radiation was found (95% CI: 1.03, 
1.22). Relative risk increased monotonically with increasing cumulative bone marrow dose, becoming 
significantly raised above around 4 mGy. The trend was driven by lymphoid leukaemia (RR=1.13, 
95% CI: 1.02, 1.24), with lower risks for myeloid leukaemia (RR=1.05, 95% CI: 0.87, 1.28). For all 
cancers except leukaemia, risks were non-significantly negative up to cumulative doses of around 12 
mGy, above which they were positive. Lest this be interpreted as evidence of hormesis (i.e. the theory 
that low doses reduce risk), it should be noted that these doses were protracted. Thus, if a hormesis 
effect or low dose threshold does exist, it is likely to be in the region of a few nanogray and of little 
significance in medical imaging. Another new background radiation study, based in Switzerland, was 
conducted by Spycher et al [68], involving 2,093,660 children aged under 16 years. A significant 
increase in incidence was reported for all cancers combined (HR = 1.64, 95% CI:1.13, 2.37) and 
leukaemia (HR= 2.04, 95% CI: 1.11, 3.74) for children residing in areas with background dose rates 
of greater than 200 nSv per hour (≈1.75 mSv per year) compared to less than 100 nSv per hour (≈0.88 
mSv per year). No corresponding increase was found for lymphoma (HR=0.91, 95% CI: 0.29, 2.86).  
Otherwise, the negative risks for low-to-moderate dose rates found in the study by Kendall et al 
described above were not seen in the Swiss study.  
 
Implications for patients and staff: 
Practical radiation protection is primarily based on the assumed association between radiation 
exposure and increased cancer risk. Recent epidemiological studies have, on balance, strengthened 
this association. While no significant change to practice is warranted, a number of recent findings 
have potentially important implications. Firstly, dose limits for members of the public and radiation 
workers are based on risk estimates calculated by the ICRP of 5.5% per Sv (effective dose) [2] that 
assume risks, per unit dose, at low doses (<200 mGy) or dose rates (<0.1 mGy per minute) are 
reduced by a factor of 2.0 compared to higher doses or dose rates [2].  These risk estimates impact 
room design considerations such as shielding requirements and designation of controlled and 
supervised areas. The results of studies of nuclear workers [69], including the new INWORKS 
analyses [53, 54], appear to challenge this assumption, suggesting a DDREF closer to 1.0. This, in 
turn, suggests dose limits should be reduced by 50%. Nuclear workers are exposed to different photon 
energies and radionuclides to medical imaging staff, including beta emitters such as strontium-90 or 
alpha emitters such as plutonium. The transferability of these findings, if true, between occupational 
groups is unclear.  
Secondly, findings of increased risk of leukaemia among children receiving CT scans, occupationally 
exposed workers or children living in high background radiation areas ought to encourage greater 
focus on bone marrow dose reduction. This is especially significant for staff given the reported lack of 
adequate coverage provided by often ill-fitting lead aprons [70]. Around 15% of active bone marrow 
is found in the arms and head of the average 40-year-old [71]. 
Thirdly, recent studies have provided more information on the modifying effect of age-at-exposure, 
suggesting the relationship is somewhat less clear cut than often assumed. For example, brain tumour 
risk was found to increase with increasing age-at-exposure in the CT study by Pearce et al [14]. A 
recent review [72] considered children to be clearly more sensitive to radiation-induced cancers than 
adults for 25% of sites, equally sensitive for 15% and less sensitive for 10%. For the remaining sites, 
the evidence was insufficient to draw conclusion, or there is little evidence of increased risk at any 
age. The majority of studies investigating the risks from low dose medical radiation have focussed on 
exposures during childhood, mainly due to the suitability of young people for epidemiological 
analysis. ERR figures from paediatric CT studies should not be directly compared with ERR figures 
from adult studies (e.g. nuclear workers) due to the different levels of follow-up. The failure to find 
new evidence of increased cancer risks following in utero exposures does not invalidate previous 
research (i.e. the Oxford Survey) nor justify abandoning current radiation protection practices for 
pregnant patients.  
 
Conclusion: 
Table 1 summarises the site specific risk of radiation induced cancer based on current evidence. 
Recent epidemiological studies, combined with existing knowledge, have strengthened the evidence 
that ionising radiation, at diagnostic dose levels, increases the risk of developing cancer. The findings 
of significantly increased cancer risks following protracted exposures among nuclear workers and 
individuals exposed to elevated background radiation levels, do not suggest the presence of a low 
dose threshold below which there is no risk. The magnitude of the risks and the shape of the dose-risk 
relationship at low doses remain very uncertain, however. It may never be possible to demonstrate the 
risks for procedures delivering localised doses below 1 mGy, such as chest or extremity radiographs, 
with adequate statistical power, nor may it be possible to rule out the possibility that the risks are zero. 
Future research, including extended background radiation studies, cohorts of children undergoing 
cardiac catheterizations [73] and Europe-wide pooling of CT cohorts with improved dosimetry, taking 
account of confounding conditions, should improve risk estimates.  
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Cancer site: Strength of 
Evidence: 
Comments: Key 
references 
Leukaemia Very strong 
Assumed to follow exposure to bone marrow. 
Increased risks following acute and protracted 
exposures. 
[14, 15, 
17, 19, 66, 
74, 75] 
Thyroid Very strong 
Strongly associated with radioiodine intake. Risk is 
much higher for young children and infants. 
[76-78] 
Breast Very strong Associated with both acute and fractionated exposures. [79] 
Lung Strong 
Strong link with occupational exposures. Risks appear 
to be higher for exposures in adulthood. 
[77, 80] 
Stomach Strong 
Large excess among LSS cohort, though problems arise 
transferring risk estimates to non-Japanese populations. 
[77, 81] 
Colon Strong 
Increased risks in LSS and radiotherapy cohorts with 
linear dose response. 
[77, 82] 
Bladder Strong 
Increased risks demonstrated in LSS and radiotherapy 
studies. 
[77, 83] 
Skin Strong 
Risks are high for basal cell carcinoma. Some evidence 
of increased melanoma risk after radiotherapy. 
[26, 84] 
Brain/CNS Moderate 
Recent findings of large risks following CT scans. 
Radiation-induced tumours tend to be benign. 
[14-20, 
24, 25, 33] 
Oesophagus Moderate Large level of uncertainty in ERR and effect of age. [77, 85] 
Ovary Moderate 
Increased rates among LSS cohort, though mixed 
evidence from other studies. Highly uncertain ERR. 
Evidence of hereditary effects is inconclusive. 
[77, 86] 
Liver Moderate 
Strong association with internal emitters such as 
plutonium or thorium. Modifying effect of age at 
exposure is unclear. 
[77, 80, 
87] 
Salivary 
glands 
Moderate 
Excesses seen among the LSS cohort and patients 
treated with radiotherapy. Dose response is unclear, 
however. Tumours tend to be benign. 
[77, 88, 
89] 
Bone/soft 
tissue 
sarcoma 
Weak 
Very well established risk following high dose 
radiotherapy, though limited evidence of risks at doses 
below 0.5-1 Gy. 
[90, 91] 
Pancreas Weak Some evidence of increased risk after radiotherapy. [92] 
Non-
Hodgkin’s 
Lymphoma 
Weak 
A few studies show non-significantly raised rates. 
Immunosuppression is a major confounding factor. 
[53, 77, 
93] 
Hodgkin’s 
lymphoma, 
testes, 
kidneys, 
prostate, 
cervix, small 
intestine, 
rectum, eyes. 
Possibly 
absent/no 
evidence 
These sites are often omitted from analyses. Increased 
risks are sometimes observed following high dose 
radiotherapy. At low doses, cancer risks are likely to be 
small, if present at all. Evidence of hereditary effects 
following exposure of the testes is inconclusive. The 
eyes are sensitive to cataract induction. 
[77, 86, 
94] 
 
Table 1: Site-specific risk of cancer from ionising radiation exposure. LSS= Life Span Study 
(Hiroshima and Nagasaki cohort). 
 
 
